Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Case register study to capture the efficacy of Ipilimumab and other therapies after treatment with Nivolumab or Pembrolizumab in Ipilimumab naive patients with stage IV or non-resectable stage III metastatic melanoma - PD-Next

Trial Profile

Case register study to capture the efficacy of Ipilimumab and other therapies after treatment with Nivolumab or Pembrolizumab in Ipilimumab naive patients with stage IV or non-resectable stage III metastatic melanoma - PD-Next

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms PD-Next
  • Most Recent Events

    • 25 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top